mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV DOI Creative Commons
Laura Matarazzo, Paulo Bettencourt

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: April 24, 2023

The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, number in preclinical and clinical development increased exponentially since 2020, including numerous improvements formulation design, delivery methods manufacturing processes. However, faces challenges such as cost raw materials, lack standardization, optimization. MRNA may provide solution to some emerging infectious diseases well deadliest hard-to-treat malaria, tuberculosis, human immunodeficiency virus/acquired syndrome (HIV/AIDS), which an effective vaccine, easily deployable endemic areas is urgently needed. In this review, we discuss functional structure, processes vaccines. We up-to-date overview diseases, immunogenicity, efficacy correlates protection vaccines, with particular focus research tuberculosis HIV.

Language: Английский

mRNA vaccines in disease prevention and treatment DOI Creative Commons
Gang Zhang, Tianyu Tang, Yinfeng Chen

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Sept. 20, 2023

Abstract mRNA vaccines have emerged as highly effective strategies in the prophylaxis and treatment of diseases, thanks largely although not totally to their extraordinary performance recent years against worldwide plague COVID-19. The huge superiority regarding efficacy, safety, large-scale manufacture encourages pharmaceutical industries biotechnology companies expand application a diverse array despite nonnegligible problems design, fabrication, mode administration. This review delves into technical underpinnings vaccines, covering synthesis, delivery, adjuvant technologies. Moreover, this presents systematic retrospective analysis logical well-organized manner, shedding light on representative employed various diseases. scope extends across infectious cancers, immunological tissue damages, rare showcasing versatility potential therapeutic areas. Furthermore, engages prospective discussion current challenge direction for advancement utilization vaccines. Overall, comprehensive serves valuable resource researchers, clinicians, industry professionals, providing understanding aspects, historical context, future prospects fight

Language: Английский

Citations

113
mRNA-based therapeutics: looking beyond COVID-19 vaccines DOI
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 403(10432), P. 1192 - 1204

Published: March 1, 2024

Language: Английский

Citations

77
Nanotechnology-based mRNA vaccines DOI Open Access
Shuying Chen, Xiangang Huang, Yonger Xue

et al.

Nature Reviews Methods Primers, Journal Year: 2023, Volume and Issue: 3(1)

Published: Aug. 17, 2023

Language: Английский

Citations

74
Clinical delivery of circular RNA: Lessons learned from RNA drug development DOI
Tiana L. Young, Kevin Chang Wang, Andrew Varley

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 197, P. 114826 - 114826

Published: April 23, 2023

Language: Английский

Citations

72
mRNA vaccines as an armor to combat the infectious diseases DOI Creative Commons

Priyanka Choudhary,

Hitesh Chopra, Om Prakash Choudhary

et al.

Travel Medicine and Infectious Disease, Journal Year: 2023, Volume and Issue: 52, P. 102550 - 102550

Published: Feb. 10, 2023

Language: Английский

Citations

68
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines DOI Creative Commons
K. Swetha, Niranjan G. Kotla, Lakshmi Tunki

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 658 - 658

Published: March 14, 2023

Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced technologies for highly efficient in vivo delivery exogenous mRNA, particularly COVID-19 vaccine delivery. LNPs comprise four different lipids: ionizable lipids, helper or neutral cholesterol, and lipids attached to polyethylene glycol (PEG). In this review, we present recent advances insights design LNPs, well their composition properties, with a subsequent discussion on development vaccines. particular, are critical drivers complexing mRNA delivery, role vaccines is discussed detail. Furthermore, use effective vehicles vaccination, genome editing, protein replacement therapy explained. Finally, expert opinion discussed, which may address future challenges developing using based novel set lipids. Developing systems improved safety against some severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains difficult.

Language: Английский

Citations

67
Recent Advancement in mRNA Vaccine Development and Applications DOI Creative Commons

Nojoud AL Fayez,

Majed S. Nassar, Abdullah A. Alshehri

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 1972 - 1972

Published: July 18, 2023

Messenger RNA (mRNA) vaccine development for preventive and therapeutic applications has evolved rapidly over the last decade. The mRVNA proven efficacy in various applications, including infectious disease, immunotherapy, genetic disorders, regenerative medicine, cancer. Many mRNA vaccines have made it to clinical trials, a couple obtained FDA approval. This emerging approach several advantages conventional methods: safety; efficacy; adaptability; bulk production; cost-effectiveness. However, is worth mentioning that delivery target site vivo degradation thermal stability are boundaries can alter their outcomes. In this review, we shed light on different types of vaccines, mode action, process optimize overcome limitations. We also explored systems focusing nanoparticle-mediated vaccine. Generally, system plays vital role enhancing stability, biocompatibility, homing desired cells tissues. addition function as vehicle, they serve compartment shields protects molecules against physical, chemical, biological activities efficiency. Finally, focused future considerations should be attained safer more efficient application underlining disadvantages current vaccines.

Language: Английский

Citations

66
US public investment in development of mRNA covid-19 vaccines: retrospective cohort study DOI Creative Commons
Hussain S. Lalani, Sarosh Nagar, Ameet Sarpatwari

et al.

BMJ, Journal Year: 2023, Volume and Issue: unknown, P. e073747 - e073747

Published: March 1, 2023

To estimate US public investment in the development of mRNA covid-19 vaccines.Retrospective cohort study.Publicly funded science from January 1985 to March 2022.National Institutes Health (NIH) Report Portfolio Online Reporting Tool Expenditures and Results (RePORTER) other databases. Government grants were scored as directly, indirectly, or not likely related four key innovations underlying vaccines-lipid nanoparticle, synthesis modification, prefusion spike protein structure, vaccine biotechnology-on basis principal investigator, project title, abstract.Direct research development, stratified by rationale, government funding agency, pre-pandemic (1985-2019) versus pandemic (1 2020 31 2022).34 NIH that directly vaccines identified. These combined with identified contracts totaled $31.9bn (£26.3bn; €29.7bn), which $337m was invested pre-pandemic. Pre-pandemic, $116m (35%) basic translational technology, Biomedical Advanced Research Development Authority (BARDA) ($148m; 44%) Department Defense ($72m; 21%) development. After started, $29.2bn (92%) funds purchased vaccines, $2.2bn (7%) supported clinical trials, $108m (<1%) manufacturing plus science.The at least develop, produce, purchase including sizeable investments three decades before through 2022. translated into millions lives saved crucial developing technology also has potential tackle future pandemics treat diseases beyond covid-19. maximize overall health impact, policy makers should ensure equitable global access publicly technologies.

Language: Английский

Citations

55
Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity DOI Creative Commons
Liusheng Wu, Xiaoqiang Li,

Xinye Qian

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(2), P. 186 - 186

Published: Feb. 12, 2024

In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells cancer therapy has become a strategy of great research interest. mRNA vaccines are potential choice for immunotherapy, due to their ability directly encode antigen proteins and stimulate strong response. However, the mode delivery lack stability key issues limiting its application. LNPs an excellent carrier, structural biocompatibility make them effective means delivering specific targets. This study summarizes progress LNP carrier-assisted targeted controlled release immunity. The role improving stability, immunogenicity, targeting is discussed. review aims systematically summarize latest immunity provide new ideas strategies as well more treatment plans patients.

Language: Английский

Citations

54
mRNA vaccines: The future of prevention of viral infections? DOI
Piotr Rzymski, Agnieszka Szuster−Ciesielska, Tomasz Dzieciątkowski

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(2)

Published: Feb. 1, 2023

Abstract Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological preparations developed using this platform. During pandemic, their administration has been proven to be a life‐saving intervention. Here, we review main advantages of mRNA vaccines, identify further technological challenges met during development platform, and provide an update on clinical progress leading vaccine candidates different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah Zika cytomegalovirus, Epstein‐Barr virus. The prospects manufacturing in low‐income countries also discussed. ongoing interest research technology likely overcome some existing for (e.g., related storage conditions immunogenicity components lipid nanoparticles) enhance portfolio diseases which classical formulations already authorized. It may open novel pathways protection infections consequences no safe efficient immunization methods currently available.

Language: Английский

Citations

52